EPIGENETIKS GENETIK BIYOINFORMATIK YAZILIM AS

Their core work

Epigenetiks is a Turkish bioinformatics software company based in Istanbul that specializes in computational analysis of genomic and epigenomic data. Their company name — combining epigenetics, genetics, and bioinformatics software — signals their core identity: they build or apply software tools for making sense of high-throughput sequencing data. In EU research networks, they contribute bioinformatics expertise for analyzing gene expression, chromatin dynamics, and microbial genomes, with particular depth in next-generation sequencing pipelines applied to pathogen biology and single-cell analysis. As a private SME participating in Marie Curie research training networks, they bridge academic computational biology and applied software development.

What they specialise in

How they've shifted over time

Their first project, MeTABLE (2014-2018), placed them in a broad bioinformatics role focused on genome and metagenome analysis with an applied industrial biology angle — discovering biocatalysts from environmental samples. By Cell2Cell (2019-2024), their work had narrowed and deepened into single-cell resolution epigenomics: chromatin state, gene expression heterogeneity, and protozoan pathogen biology — a shift from broad environmental genomics toward high-resolution cellular-level analysis. The trajectory suggests a deliberate move from generalist bioinformatics into specialized epigenomics and pathogen-focused computational biology.

They are moving toward increasingly specialized single-cell and epigenomic analysis capabilities, making them a relevant partner for future projects in infectious disease genomics, cell-state heterogeneity, or chromatin biology that require dedicated bioinformatics software expertise.

How they like to work

Epigenetiks has participated exclusively as a consortium member, never as project coordinator — consistent with a small specialist software company that joins larger research networks to contribute targeted computational expertise rather than to lead broad research programs. They have worked with 17 distinct partners across 11 countries through just two projects, suggesting they plug into well-connected MSCA networks rather than building a recurring inner circle of the same collaborators. For a future partner, this means they are accustomed to operating as a focused technical contributor within diverse international consortia.

Across two MSCA projects, Epigenetiks has connected with 17 unique partners spanning 11 countries, an unusually broad reach for such a small organization — a direct result of MSCA networks which tend to include many academic and industrial nodes. No geographic concentration is identifiable from the data.

What sets them apart

Epigenetiks is one of very few Turkish private SMEs in the H2020 bioinformatics space participating in Marie Curie training and mobility networks — typically dominated by universities and research institutes. This positions them as a rare industry-side bioinformatics partner for academic consortia that need software development capacity or applied computational biology expertise in Turkey. Their name explicitly anchors them at the intersection of epigenetics and software, a combination that is commercially relevant as epigenomic data analysis becomes a standard tool in drug discovery and diagnostics.

Highlights from their portfolio

• Cell2Cell
  The larger of their two funded projects (EUR 235,248, running to 2024), it tackles a fundamental question in pathogen biology — how single-cell chromatin heterogeneity drives infection success — placing Epigenetiks at the frontier of single-cell epigenomics and infectious disease research.
• MeTABLE
  Their entry point into EU research, this MSCA-RISE project combined metagenomics with biocatalyst discovery, demonstrating their ability to contribute bioinformatics tools to applied industrial biology as well as basic research.